To validate the specific role of inhibiting the interaction between KMT2A and WDR5 in the development of pulmonary fibrosis, we administered the KMT2A competitive inhibitor mm102 as an intervention treatment in a pulmonary fibrosis mouse model. Here, WDR5 is linked to pulmonary fibrosis.